Navigation Links
Can two killers make a cure?

Regulators in the US could soon be asked to approve a human trial of gene therapy for cystic fibrosis that uses a hybrid of the HIV and Ebola viruses. Tests on monkeys show the hybrid virus delivers genes to the lungs far more efficiently than any other method developed so far. And while the idea of combining two killer viruses sounds horrifying, the risks should be low.

Despite much effort, no one has managed to develop an effective form of gene therapy to treat the lung problems of people with cystic fibrosis. The condition is caused by a mutation in the CFTR gene, and one of the problems in developing a treatment is getting a working version of CFTR into a high enough proportion of cells to restore normal lung function.

While HIV is good at adding genes to cells' genomes, it does not target lung epithelial cells. Ebola binds strongly to these cells, so Gary Kobinger at the University of Pennsylvania in Philadelphia tried adding a surface protein from Ebola to HIV. Initial tests on mice showed the hybrid virus was very efficient: the gene it carried was active in 24 per cent of airway cells after two months, a far better proportion than achieved by other delivery methods (New Scientist, 10 March 2001, p 19).

But will it work in humans? The team has now done the next best thing and used the hybrid virus to deliver a test gene, lacZ, to the lungs of monkeys. After two months the gene was active in 21 per cent of cells, Kobinger told New Scientist. He is preparing the results for publication.

"The gap between monkeys and humans is much smaller than from mice to monkeys," says Ray Pickles, a gene therapy researcher at the University of North Carolina, Chapel Hill. "This could be in human trials pretty soon."

Kobinger now plans a more extensive monkey trial to convince the US Food and Drug Administration that human trials will be safe. The hybrid virus is created by adding HIV RNA, a stripped-down version of the Ebola surface prot ein RNA and the therapeutic gene to cells. The hybrid virus then self-assembles. Crucially, only the therapeutic gene is incorporated into the hybrid virus, so it cannot replicate.

All attempts in the lab to force such viruses to regain the ability to replicate have failed. Even if this did happen in the body, the resulting virus would resemble HIV, as the hybrid contains no Ebola genes - and HIV cannot infect lung cells. If it did get into the blood, where normal HIV thrives, such a virus would not replicate as efficiently as wild-type HIV. While the patient might suffer, the virus could never reach high enough levels in the body to infect others, Pickles says.

The biggest risk is that if a patient becomes infected with wild-type HIV, the wild-type virus and the hybrid could somehow merge, but such recombination has never been observed in HIV.

Despite his confidence that the hybrid will be safe, Pickles has abandoned similar research as he fears opposition from a fearful public will prevent the method ever being used. Another problem with Kobinger's approach is that patients will require repeated treatments, because the added gene ends up in surface cells that die off after a few months. Other teams are trying to find ways of targeting the progenitor cells that give rise to the surface cells.


'"/>

Source:New Scientist Boston office


Related biology news :

1. Thinking the pain away? Study shows the brains painkillers may cause placebo effect
2. Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack
3. Brazilians sequence genes of pig and poultry killers
4. A new target for painkillers
5. FDA causes unnecessary scare about common painkillers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/23/2017)... ... 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), a ... “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will lead ... Floyd’s career has spanned 30 years in the chemicals and equipment industries. Sig ...
(Date:3/22/2017)... Calif. , March 22, 2017  UBM ... proud to announce their extended partnership and the ... be headlined by the 21 st Annual ... Boston, taking place May 3-4, 2017. ... Medical Technology Association (ADVAMED) President and CEO, ...
Breaking Biology Technology: